mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
<jats:p>The successful development of several coronavirus disease 2019 (COVID-19) vaccines has substantially reduced morbidity and mortality in regions of the world where the vaccines have been deployed. However, in the wake of the emergence of viral variants that are able to evade vaccine-ind...
Main Authors: | Kaplonek, Paulina, Cizmeci, Deniz, Fischinger, Stephanie, Collier, Ai-ris, Suscovich, Todd, Linde, Caitlyn, Broge, Thomas, Mann, Colin, Amanat, Fatima, Dayal, Diana, Rhee, Justin, de St Aubin, Michael, Nilles, Eric J, Musk, Elon R, Menon, Anil S, Saphire, Erica Ollmann, Krammer, Florian, Lauffenburger, Douglas A, Barouch, Dan H, Alter, Galit |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biological Engineering |
Format: | Article |
Language: | English |
Published: |
American Association for the Advancement of Science (AAAS)
2023
|
Online Access: | https://hdl.handle.net/1721.1/147865 |
Similar Items
-
Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
by: Ilias Mavrovouniotis, et al.
Published: (2023-02-01) -
Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors
by: Madison Ballman, BA, et al.
Published: (2021-10-01) -
Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
by: Chapin S. Korosec, et al.
Published: (2022-12-01) -
Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2
by: Ilir Alimehmeti
Published: (2021-01-01) -
Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
by: Nazmul Islam, et al.
Published: (2022-05-01)